The scale-X™ bioreactor is now part of Univercells Technologies

The scale-X™ bioreactor is now part of Univercells Technologies


Comparison between scale-X™ bioreactors and microcarrier cultivations

In viral vaccines production, anchorage-dependent cell lines, such as Vero cells are commonly used. Most viral vaccine manufacturing processes are therefore based on surface-dependent cell platforms. Typical cultivation systems such as roller bottles, multi-tray cell culture dishes and microcarrier bioreactors have constraints for large-scale production.

To overcome potential scale-up limitations and to ease manufacturing, fixed-bed bioreactors are a valuable alternative.

In comparison to randomly packed fabric strips found in commonly used fixed-bed bioreactors, the proprietary scale-X™ technology uses a structured, spiral wound fixed-bed to reduce local over compaction and dead zones, while making optimal usage of available surface area with high batch-to-batch reproducibility.

scale-X single-used fixed-bed bioreactor for viral culture - enhanced upstream production - Univercells biotech Belgium


Univercells Technologies scale-X bioreactor fixed-bed Vero cells

Delivering homogeneous cell growth and scalable adherent cell culture

A homogenous cell growth is an important scaling factor. It allows maximum use of an available surface area in a reproducible manner. Ensuring an optimized cell culture can directly influence the yield and productivity of viral particles for vaccine manufacturing.

A study was carried out to compare adherent Vero cell culture in a scale-X hydro bioreactor (2.4 m²) with standard microcarrier cultivations. Univercells has extended this study with complementary cell growth profiles among the scale-X bioreactor range (from 2.4 m² to 30 m²). The valuable obtained results demonstrate the reproducibility and homogeneity of cell growth within scale-X bioreactors, making it a suitable alternative to traditional “scale-out” technologies.

About Univercells Technologies

Univercells Technologies is a global provider of innovative biomanufacturing technologies to achieve cost-effective viral production from R&D to commercial scales. The company offers a comprehensive technology portfolio leveraging the strengths of process intensification and chaining as a direct answer to the growing demand of viral vectors and viral vaccines. Univercells Technologies is committed to helping customers increase performance with minimized footprint and costs today, while anticipating the needs of tomorrow.

Building upon years of expertise and capitalizing on technology vetted by world leaders, Univercells Technologies was incorporated in Belgium in 2020 with the support of the Univercells group.

LinkedIn: Univercells Technologies


  • Application note
    | Scale-X

    scale-X™ bioreactor for Vero cell growth

    Proof of concept for scalable and homogeneous Vero cell growth in scale-X hydro (2.4 m²) and carbo (10 m² and 30 m²)